Human antibodies produced in genetically designed cows can protect against deadly diseases December 3, 2014 SAB Biotherapeutics, Inc. (SAB), a leading biopharmaceutical development company, has teamed up with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to address the potentially deadly hantavirus using a novel approach to developing protective antibodies against it. Their work, published in the November …
New vaccine generates strong immune response against hepatitis C
A new hepatitis C vaccine has shown promising results in an early clinical trial at Oxford University, generating strong and broad immune responses against the virus causing the disease November 5, 2014 The vaccine was found to be very safe and well tolerated in the 15 healthy human volunteers who took part in the phase 1 safety trial. A trial …
Celldex’s Phase 1 Study of CDX-1401 Published in Science Translational Medicine
First clinical study to demonstrate that an off-the-shelf vaccine targeting dendritic cells can safely lead to robust humoral and cellular immunity April 16, 2014 Celldex Therapeutics, Inc. announced today that final data from its Phase 1 study of CDX-1401 in solid tumors, including long-term patient follow-up, have been published inĀ Science Translational MedicineĀ (Vol 6 Issue 232). The data demonstrate robust antibody …